161 research outputs found
Best Practice Guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies
Meeting participants: RosĂĄrio dos Santos, Porto, PortugalIntroduction: A meeting of 29 senior scientists from Europe, the USA, India
and Australia, was held in Naarden, The Netherlands on November
14â16, 2008, to establish consensus Best Practice Guidelines for
molecular diagnosis of Duchenne and Becker muscular dystrophy
(DMD/BMD). New therapeutic trials for DMD demand accurate
diagnosis of the disorder, especially where the therapy is targeted
towards specific mutations. These guidelines aim to help diagnostic
laboratories attain that accuracy by describing the minimum
standards for acceptable molecular diagnostic testing of DMD.
For the different types of clinical referral received by a molecular
diagnostic laboratory, the guidelines recommend the appropriate
tests to be carried out, interpretation of the results and how those
results should be reported.The workshop was jointly organised and sponsored by The European Molecular Genetics Quality Network (www.emqn.org); Euro-
Gentest (www.eurogentest.org); EU Contract no. FP6-512148); TREAT-NMD (www.treat-nmd.org); EU Contract no. FP6-036825),
and hosted by the European Neuro-Muscular Centre (www.enmc.org)
Guidance in social and ethical issues related to clinical, diagnostic care and novel therapies for hereditary neuromuscular rare diseases: "translating" the translational.
Drug trials in children engage with many ethical issues, from drug-related safety concerns to communication with patients and parents, and recruitment and informed consent procedures. This paper addresses the field of neuromuscular disorders where the possibility of genetic, mutation-specific treatments, has added new complexity. Not only must trial design address issues of equity of access, but researchers must also think through the implications of adopting a personalised medicine approach, which requires a precise molecular diagnosis, in addition to other implications of developing orphan drugs. It is against this background of change and complexity that the Project Ethics Council (PEC) was established within the TREAT-NMD EU Network of Excellence. The PEC is a high level advisory group that draws upon the expertise of its interdisciplinary membership which includes clinicians, lawyers, scientists, parents, representatives of patient organisations, social scientists and ethicists. In this paper we describe the establishment and terms of reference of the PEC, give an indication of the range and depth of its work and provide some analysis of the kinds of complex questions encountered. The paper describes how the PEC has responded to substantive ethical issues raised within the TREAT-NMD consortium and how it has provided a wider resource for any concerned parent, patient, or clinician to ask a question of ethical concern. Issues raised range from science related ethical issues, issues related to hereditary neuromuscular diseases and the new therapeutic approaches and questions concerning patients rights in the context of patient registries and bio-banks. We conclude by recommending the PEC as a model for similar research contexts in rare diseases
Establishing the accuracy of asteroseismic mass and radius estimates of giant stars III. KIC4054905, an eclipsing binary with two 10 Gyr thick disk RGB stars
Eclipsing binary stars with an oscillating giant component allow accurate
stellar parameters to be derived and asteroseismic methods to be tested and
calibrated. To this aim, suitable systems need to be firstly identified and
secondly measured precisely and accurately. KIC 4054905 is one such system,
which has been identified, but with measurements of a relatively low precision
and with some confusion regarding its parameters and evolutionary state. Our
aim is to provide a detailed and precise characterisation of the system and to
test asteroseismic scaling relations. Dynamical and asteroseismic parameters of
KIC4054905 were determined from Kepler photometry and multi-epoch
high-resolution spectra from FIES at the Nordic Optical Telescope. KIC 4054905
was found to belong to the thick disk and consist of two lower red giant branch
(RGB) components with nearly identical masses of 0.95 and an age of
Gyr. The most evolved star displays solar-like oscillations, which
suggest that the star belongs to the RGB, supported also by the radius, which
is significantly smaller than the red clump phase for this mass and
metallicity. Masses and radii from corrected asteroseismic scaling relations
can be brought into full agreement with the dynamical values if the RGB phase
is assumed, but a best scaling method could not be identified. We measured
dynamical masses and radii with a precision better than 1.0%. We firmly
establish the evolutionary nature of the system to be that of two early RGB
stars with an age close to 10 Gyr, unlike previous findings. The metallicity
and Galactic velocity suggest that the system belongs to the thick disk of the
Milky Way. We investigate the agreement between dynamical and asteroseismic
parameters for KIC 4054905. Consistent solutions exist, but the need to analyse
more systems continues in order to establish the accuracy of asteroseismic
methods.Comment: Accepted for publication in Astronomy & Astrophysics, 11 pages, 3
figure
Glucose metabolite glyoxal induces senescence in telomerase-immortalized human mesenchymal stem cells
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
Aim: We investigated the effect of ataluren plus standard of care (SoC) on age at loss of ambulation (LoA) and respiratory decline in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) versus patients with DMD on SoC alone. / Patients & methods: Study 019 was a long-term Phase III study of ataluren safety in nmDMD patients with a history of ataluren exposure. Propensity score matching identified Study 019 and CINRG DNHS patients similar in disease progression predictors. / Results & conclusion: Ataluren plus SoC was associated with a 2.2-year delay in age at LoA (p = 0.0006), and a 3.0-year delay in decline of predicted forced vital capacity to <60% in nonambulatory patients (p = 0.0004), versus SoC. Ataluren plus SoC delays disease progression and benefits ambulatory and nonambulatory patients with nmDMD. / ClinicalTrials.gov: NCT01557400
Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy.
Aim: Assess the totality of efficacy evidence for ataluren in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD).
Materials & methods: Data from the two completed randomized controlled trials (ClinicalTrials.gov: NCT00592553; NCT01826487) of ataluren in nmDMD were combined to examine the intent-to-treat (ITT) populations and two patient subgroups (baseline 6-min walk distance [6MWD] \u3e= 300-\u3c400 or \u3c400 m). Meta-analyses examined 6MWD change from baseline to week 48.Results:Statistically significant differences in 6MWD change with ataluren versus placebo were observed across all three meta-analyses. Least-squares mean difference (95% CI): ITT (n = 342), +17.2 (0.2-34.1) m, p = 0.0473; \u3e= 300-\u3c400 m (n = 143), +43.9 (18.2-69.6) m, p = 0.0008; \u3c400 m (n = 216), +27.7 (6.4-49.0) m, p = 0.0109.
Conclusion: These meta-analyses support previous evidence for ataluren in slowing disease progression versus placebo in patients with nmDMD over 48 weeks. Treatment benefit was most evident in patients with a baseline 6MWD \u3e= 300-\u3c400 m (the ambulatory transition phase), thereby informing future trial design
Characterization of pulmonary function in 10â18 year old patients with Duchenne muscular dystrophy
Pulmonary function loss in patients with Duchenne muscular dystrophy (DMD) is progressive and leads to pulmonary insufficiency. The purpose of this study in 10â18 year old patients with DMD is the assessment of the inter-correlation between pulmonary function tests (PFTs), their reliability and the association with the general disease stage measured by the Brooke score. Dynamic PFTs (peak expiratory flow [PEF], forced vital capacity [FVC], forced expiratory volume in one second [FEV1]) and maximum static airway pressures (MIP, MEP) were prospectively collected from 64 DMD patients enrolled in the DELOS trial (ClinicalTrials.gov, number NCT01027884). Baseline PEF percent predicted (PEF%p) was <80% and patients had stopped taking glucocorticoids at least 12 months prior to study start. At baseline PEF%p, FVC%p and FEV1%p correlated well with each other (Spearman's rho: PEF%pâFVC%p: 0.54; PEF%pâFEV1%p: 0.72; FVC%pâFEV1%p: 0.91). MIP%p and MEP%p correlated well with one another (MIP%pâMEP%p: 0.71) but less well with PEF%p (MIP%pâPEF%p: 0.40; MEP%pâPEF%p: 0.41) and slightly better with FVC%p (MIP%pâFVC%p: 0.59; MEP%pâFVC%p: 0.74). The within-subject coefficients of variation (CV) for successive measures were 6.97% for PEF%p, 6.69% for FVC%p and 11.11% for FEV1%p, indicating that these parameters could be more reliably assessed compared to maximum static airway pressures (CV for MIP%p: 18.00%; MEP%p: 15.73%). Yearly rates of PFT decline (placebo group) were larger in dynamic parameters (PEF%p: â8.9% [SD 2.0]; FVC%p: â8.7% [SD 1.1]; FEV1%p: â10.2% [SD 2.0]) than static airway pressures (MIP%p: â4.5 [SD 1.3]; MEP%p: â2.8 [SD 1.1]). A considerable drop in dynamic pulmonary function parameters was associated with loss of upper limb function (transition from Brooke score category 4 to category 5). In conclusion, these findings expand the understanding of the reliability, correlation and evolution of different pulmonary function measures in DMD patients who are in the pulmonary function decline phase
RARE-Bestpractices: a platform for sharing best practices for the management of rare diseases
From 7th European Conference on Rare Diseases and Orphan Products (ECRD 2014).Rare diseases; clinical practice guidelines; recommendations. RARE-Bestpractices (http://www.rarebestpractices.eu) is a 4-year project (2013-2016) funded by the EC FP7. The project aims at improving clinical management of patients with rare diseases (RD) and at narrowing the existing gap in quality of healthcare among countries. Methods: RARE-Bestpractices (http://www.rarebestpractices.eu) involves 9 EU countries, including 15 partners from academic institutions, governmental bodies, patient organizations and networks, which will exploit the added value of integrating different contributions and viewpoints. The platform is developed involving both experts in RD research as well as experts in clinical practice guidelines (CPG) and systematic reviews. Results: Project expected outputs include: 1) identification of challenges to be considered in deriving high quality standards for CPG on RD; 2) transparent procedures and criteria for the evaluation of CPG and their collection in a publicly searchable database; 3) identification of notation criteria to improve user understandability and implementation of CPG; 4) production of mechanisms to assess RD clinical research needs; 5) development of training activities targeted to key stakeholders to disseminate process and tools for developing and evaluating CPG; 6) the publication of a new scientific journal (http://rarejournal.org). Discussion: RARE-Bestpractices addresses the demands from both patients and health care providers for updated and high quality CPG on RD. The project will meet the requirements laid down by to the Directive 2011/24/EU, which endorses EU MS to develop European Reference Networks (ERNs) for RD; in fact, one main criterion for ERNs should be the competence to produce CPG and actively disseminate them among Centers of Expertise.N
- âŚ